Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Non-Current Debt (2019 - 2021)

VYNE Therapeutics (VYNE) has disclosed Non-Current Debt for 3 consecutive years, with $33.3 million as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Non-Current Debt rose 1.39% year-over-year to $33.3 million, compared with a TTM value of $33.3 million through Mar 2021, up 1.39%, and an annual FY2020 reading of $33.2 million, up 1.37% over the prior year.
  • Non-Current Debt was $33.3 million for Q1 2021 at VYNE Therapeutics, roughly flat from $33.2 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $33.3 million in Q1 2021 and bottomed at $32.7 million in Q4 2019.
  • Average Non-Current Debt over 3 years is $33.0 million, with a median of $33.0 million recorded in 2020.
  • The sharpest move saw Non-Current Debt increased 1.37% in 2020, then rose 1.39% in 2021.
  • Year by year, Non-Current Debt stood at $32.7 million in 2019, then increased by 1.37% to $33.2 million in 2020, then increased by 0.3% to $33.3 million in 2021.
  • Business Quant data shows Non-Current Debt for VYNE at $33.3 million in Q1 2021, $33.2 million in Q4 2020, and $33.0 million in Q3 2020.